Program
brivaracetam
Also written as “Brivaracetam”, “Brivaracetam Film-coated tablet” and “Brivaracetam oral solution”.
Its studies are mostly in Epilepsy · Epilepsy, Absence · Epilepsies, Partial · Myoclonus · Seizures, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCB | 392 open or running | phase 3since Sep 6, 2005 | Sep 6, 2005 | Nov 16, 2029phase 3 · NCT06315322 |
| Overseas Pharmaceuticals | 10 open or running | phase 1since Nov 11, 2022 | Nov 11, 2022 | none ahead |
| Qingfeng Pharmaceutical Group | 10 open or running | phase 3since Apr 17, 2026 | Apr 17, 2026 | none ahead |
| Sino Biopharmaceutical | 11 open or running | phase 1since Dec 23, 2024 | Dec 23, 2024 | none ahead |
Also a collaborator on its studies: pra-health-sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 28 studies since Sep 6, 2005.
- Jul 31, 2017Phase 3 study in EpilepsyUCB · NCT03250377 · 207 enrolled · China, Japan
- Oct 25, 2017Phase 3 study in EpilepsyUCB · NCT03325439 · 9 enrolled · Belgium, Czechia, France and more
- Jan 12, 2018Phase 2 study in EpilepsyUCB · NCT03405714 · 50 enrolled · United States, Czechia, Germany and more
- Sep 20, 2018Phase 3 study in EpilepsyUCB · NCT03685630 · 10 enrolled · Japan
- Dec 7, 2020Phase 3 study in Epilepsy, AbsenceUCB · NCT04666610 · 154 enrolled · United States, Georgia, Italy and more
- Jan 14, 2021Phase 3 study in EpilepsyUCB · NCT04715646 · 70 planned · United States, Belgium, Czechia and more
- May 6, 2021Phase 1 study in EpilepsyUCB · NCT04882540 · 12 enrolled · China
- Oct 25, 2021Phase 3 study in Epilepsy, AbsenceUCB · NCT05109234 · 84 enrolled · United States, Georgia, Italy and more
- Mar 14, 2022Phase 1 study in Healthy Study ParticipantsUCB · NCT05315947 · 24 enrolled · Japan
- Nov 11, 2022Overseas Pharmaceuticals's first study: phase 1 study in SeizuresNew to Overseas PharmaceuticalsOverseas Pharmaceuticals · NCT05622370 · 12 enrolled · China
- Mar 8, 2024Phase 1 study in Healthy Study ParticipantsUCB · NCT06312566 · 64 enrolled · Japan
- Mar 11, 2024Phase 3 study in Epilepsy, AbsenceUCB · NCT06315322 · 70 enrolled · United States, Georgia, Italy and more
- Dec 23, 2024Sino Biopharmaceutical's first study: phase 1 study in EpilepsyNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT06762743 · 60 planned · China
- Apr 17, 2026Qingfeng Pharmaceutical Group's first study: phase 3 study in Epilepsies, PartialNew to Qingfeng Pharmaceutical GroupQingfeng Pharmaceutical Group · NCT07563634 · 141 enrolled · China
Ahead
- Nov 16, 2029Primary completion: phase 3 study in Epilepsy, AbsenceUCB · NCT06315322
- Jul 8, 2030Primary completion: phase 3 study in EpilepsyUCB · NCT04715646
TargetBeta
“Synaptic vesicle glycoprotein 2A modulator”ChEMBL 37, by rule
Other programs on SV2A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Levetiracetamrule | UCB | phase 4 | 73 |
Studies
All 42 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07563634Epilepsies, Partial · China | 3 | Completed | Qingfeng Pharmaceutical Group | May 21, 2024 | 141 |
| NCT06762743Epilepsy · China | 1 | By invitation | Sino Biopharmaceutical | Dec 31, 2024 | 60 |
| NCT06315322Epilepsy, Absence · United States, Georgia, Italy and more | 3 | Active, not recruiting | UCB | Nov 16, 2029 | 70 |
| NCT06312566Healthy Study Participants · Japan | 1 | Completed | UCB | Jun 4, 2024 | 64 |
| NCT05622370Seizures · China | 1 | UNKNOWN | Overseas Pharmaceuticals | Mar 30, 2023 | 12 |
| NCT05315947Healthy Study Participants · Japan | 1 | Completed | UCB | May 13, 2022 | 24 |
| NCT05109234Epilepsy, Absence · United States, Georgia, Italy and more | 3 | Completed | UCB | Mar 18, 2025 | 84 |
| NCT04882540Epilepsy · China | 1 | Completed | UCB | Jun 8, 2021 | 12 |
| NCT04715646Epilepsy · United States, Belgium, Czechia and more | 3 | Recruiting | UCB | Jul 8, 2030 | 70 |
| NCT04666610Epilepsy, Absence · United States, Georgia, Italy and more | 3 | Completed | UCB | Jul 7, 2026 | 154 |
| NCT03685630Epilepsy · Japan | 3 | Completed | UCB | Mar 27, 2021 | 10 |
| NCT03405714Epilepsy · United States, Czechia, Germany and more | 2 | Completed | UCB | Nov 4, 2020 | 50 |
| NCT03325439Epilepsy · Belgium, Czechia, France and more | 3 | Terminated | UCB | Sep 3, 2020 | 9 |
| NCT03250377Epilepsy · China, Japan | 3 | Completed | UCB | Dec 24, 2024 | 207 |
| NCT03083665Epilepsy · China, Japan, Malaysia and more | 3 | Completed | UCB | Jun 30, 2022 | 449 |
| NCT03021018Epilepsy · United States | 2 | Completed | UCB | Apr 27, 2018 | 46 |
| NCT02602860Healthy Volunteers · United States | 1 | Completed | UCB | Sep 2017 | 13 |
| NCT02088957Nonconvulsive Electrographic Seizures · United States | 2 | Terminated | UCB | Oct 2014 | 1 |
| NCT01728077Epilepsy · United States, France, Germany and more | 3 | Completed | UCB | Aug 2016 | 26 |
| NCT01710670Healthy Volunteers · Netherlands | 1 | Completed | UCB | Nov 2012 | 18 |
| NCT01653262Epilepsy · United States, France, Germany and more | 3 | Completed | UCB | Nov 2013 | 29 |
| NCT01405508Epilepsy · United States, Czechia, Germany and more | 3 | Completed | UCB | Jul 2012 | 105 |
| NCT01364597Epilepsy · United States, Belgium, Czechia and more | 3 | Completed | UCB | Feb 3, 2022 | 257 |
| NCT01339559Epilepsy · United States, Austria, Belgium and more | 3 | Completed | UCB | Apr 18, 2019 | 767 |
| NCT01261325Epilepsy · United States, Austria, Belgium and more | 3 | Completed | UCB | May 2014 | 768 |
| NCT00761774Epilepsy · United States, Australia, Belgium and more | 3 | Completed | UCB | Mar 2017 | 108 |
| NCT00736931Epilepsy · United States | 1 | Completed | UCB | Oct 2008 | 20 |
| NCT00699283Epilepsy · United States, France, Germany and more | 3 | Terminated | UCB | Mar 2010 | 62 |
| NCT00698581Epilepsy · United States, Australia, Belgium and more | 3 | Terminated | UCB | Jan 2010 | 88 |
| NCT00504881Epilepsy · Austria, Belgium, Czechia and more | 3 | Completed | UCB | Nov 2008 | 480 |
| NCT00490035Epilepsy · Belgium, Finland, France and more | 3 | Completed | UCB | Feb 2009 | 399 |
| NCT00464269Epilepsy · United States, Australia, Brazil and more | 3 | Completed | UCB | Dec 2008 | 400 |
| NCT00426673Epilepsy · United States | 1 | Completed | UCB | Jun 2006 | 15 |
| NCT00422422Epilepsy · United States, Belgium, Czechia and more | 2 | Completed | UCB | Mar 2013 | 100 |
| NCT00401648Epilepsy · France, Germany | 2 | Completed | UCB | Jun 2003 | 20 |
| NCT00368251Unverricht-Lundborg Syndrome · United States, Canada, Finland and more | 3 | Completed | UCB | Jan 2008 | 56 |
| NCT00357669Unverricht-Lundborg Syndrome · Finland, France, Italy and more | 3 | Completed | UCB | Oct 2007 | 50 |
| NCT00175929Epilepsies, Partial · Belgium, Czech Republic, Finland and more | 2 | Completed | UCB | Mar 2006 | 157 |
| NCT00175916Epilepsy · United States, Austria, Belgium and more | 3 | Completed | UCB | May 2019 | 853 |
| NCT00175825Epilepsy · United States, Brazil, India and more | 2 | Completed | UCB | Jun 29, 2006 | 210 |
| NCT00160667Neuralgia, Postherpetic · Belgium, Bulgaria, Czechia and more | 2 | Completed | UCB | Jan 5, 2006 | 152 |
| NCT00150800Epilepsy · United States, Australia, Brazil and more | 3 | Completed | UCB | Sep 2017 | 668 |
How it is read
Names in the registry
- “Brivaracetam”, 33 entries
- “brivaracetam”, 3 entries
- “Brivaracetam Film-coated tablet”, 2 entries
- “Brivaracetam oral solution”, 2 entries
- “Brivaracetam 25 mg”, 2 entries
Conditions, from the studies’ own filings
- Epilepsy, 28 studies
- Epilepsy, Absence, 3 studies
- Epilepsies, Partial, 2 studies
- Myoclonus, 2 studies
- Seizures, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.